Senior Leader Positioning Bio/Pharmaceutical Organizations to Capture Competitive Advantage Board of Directors | Chief Scientific Officer | Drug Development Leader | C-SuiteE: Lurgan@optonline.net Drug development expert with over 25 years of experience driving the development, launch, and lifecycle management of groundbreaking therapies, including ZESTRIL, ZESTORETIC, DIOVAN, SEROQUEL, TRILEPTAL, GILENYA, EXELON, ZOMETA, CASODEX, ARIMIDEX, ACCOLATE, FORADIL, and XOLAIR .Inspiring, authentic leader with extensive expertise bringing blockbuster therapies to market; broad experience spans multiple therapeutic areas including CVM, Neurology/CNS, Bone Health, Oncology, Women’s Health, and Respiratory health. An M&A strategist who structures organizations for optimal efficiency and performance, I am passionate about building organizations and cultures that foster excellence, challenging leaders to achieve peak performance, and driving metrics-based change. KEY STRENGTHS • Managing Regulatory Approval• Driving Launch Strategy• Engaging KOL’s• Developing Talent• Leading Change• Building Branded Portfolios• Cultivating InnovationCAREER HIGHLIGHTS INCLUDE• Advanced through senior-level roles in drug development at Zeneca and AstraZeneca, providing cross-portfolio international leadership for approval, launch, and lifecycle management of pioneering blockbusters.• As CSO at Novartis Corp, restructured drug development to align clinical development and medical affairs under six therapeutic areas and created a best-in-class clinical organization.• As board and executive advisor, played a key role high-value acquisitions, including Chase’s acquisition by Allergan in a deal worth up to $1B.